TickerWise

AIDX — 20/20 Biolabs, Inc. Common Stock

$0.2325-1.15%

Last close: · regular session

Last 60 sessions

AIDX closed at $0.2325 (-1.15%) on Oct 26, 2026. Float: 10.6M shares. Latest SEC filing: 10-Q on Aug 14, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for AIDX in the TickerWise workspace.

20/20 GeneSystems, Inc. operates as a specialized clinical diagnostic company, focusing primarily on screening for cancer and analyzing viral infections. The firm offers advanced blood tests for the early detection of various cancers, including a notable product called OneTest. Additionally, it provides services for identifying viruses, such as rapid COVID-19 test kits like the Assure COVID-19 IgG/IgM rapid assay. The company also manages the Clinical Lab Innovation Axcelerator (CLIAx), a collaborative laboratory space designed to help developers of diagnostic products bring their innovations to the U.S. market. Furthermore, 20/20 GeneSystems delivers its cancer screening algorithm technology to healthcare providers via a software-as-a-service (SaaS) platform. It actively supports emerging diagnostic startups by offering them access to shared lab infrastructure and vital resources. Founded in 2000, the company is headquartered in Gaithersburg, Maryland.

Company profile

Latest SEC filings for AIDX

Related companies

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.